Replies to post #118446 on Biotech Values

[DewDiligence]

[AMR101] doesn't seem it is as attractive to these two [GSK and ABT] as to say others like PFE, MRK, AZN from my point of view, thus I highly doubt they can outbid other big pharmas in similar space.

I fully agree with respect to GSK, but not with respect to ABT. These two are not in the same boat, IMO.

I’m not sure PFE would be interested insofar as they announced their planned exit from the CV arena a few years ago.

[DewDiligence]

In light of #msg-62635406, your mentioning PFE in the context of #msg-62213080 makes more sense.